This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Bydureon
  • /
  • Energy Balance in Craniopharyngioma-related Hypoth...
Clinical trial

Energy Balance in Craniopharyngioma-related Hypothalamic Obesity (ECHO)

Read time: 2 mins
Last updated:1st Mar 2016

The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind, placebo-controlled 36 week randomized trial with an 18 week open label extension. Following baseline testing, 48 patients will be randomly assigned with equal allocation to ExQW or matching placebo injection for 36 weeks, followed by an 18 week open label extension during which all patients receive ExQW. Changes of weight status, body composition, free-living total daily energy expenditure (EE) by doubly labeled water (DLW), activity by acetimetry, energy intake (questionnaires and food diary), as well as glucose tolerance and hormonal parameters of energy homeostasis and insulin resistance will be assessed before treatment and at the end of the placebo-controlled phase (week 36). Activity, metabolic outcomes, energy intake will be also assessed at study week 18 (mid treatment of randomized study), as well as week 54 (end of open label treatment).

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity
Estimated Enrollment: 48
Study Start Date: March 2016
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)

- Active Comparator:
Exenatide once weekly extended-release
- Placebo Comparator: Matching placebo

Category Value
Study start date 2016-03-01

View full details